J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Molecular Pharmacology

• Publication date

  1998-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/MOL.54.1.1PMID 9658183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new class of highly potent farnesyl diphosphate-competitive inhibitors of farnesyltransferase.

  1998cited by this paper
• Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo *

  1997cited by this paper
• Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I*

  1997cited by this paper
• C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

  1997cited by this paper
• The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.

  1997cited by this paper
• Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.

  1996cited by this paper
• Protein prenylation: molecular mechanisms and functional consequences.

  1996cited by this paper
• J-104,123, a novel and orally-active inhibitor of squalene synthase: Stereoselective synthesis and cholesterol lowering effects in dogs

  1996cited by this paper
• Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.

  1995cited by this paper
• Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.

  1995cited by this paper
• Novel Tricyclic Inhibitors of Farnesyl Protein Transferase

  1995cited by this paper
• A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

  1995cited by this paper
• Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*)

  1995cited by this paper
• Synthesis and biological activity of J-104,118, a novel, potent inhibitor of squalene synthase

  1995cited by this paper
• Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.

  1994cited by this paper
• Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type I.

  1994cited by this paper
• Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase.

  1993influential reference
• Peptidomimetic inhibitors of Ras farnesylation and function in whole cells.

  1993cited by this paper
• Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.

  1993cited by this paper
• Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.

  1993cited by this paper
• Function and regulation of ras.

  1993cited by this paper
• Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

  1992cited by this paper
• Steady-state kinetic mechanism of Ras farnesyl:protein transferase.

  1992cited by this paper
• ras and human tumors.

  1992cited by this paper
• The GTPase superfamily: conserved structure and molecular mechanism

  1991cited by this paper
• Ras C-terminal processing enzymes--new drug targets?

  1991cited by this paper
• Nonidentical subunits of p21H-ras farnesyltransferase. Peptide binding and farnesyl pyrophosphate carrier functions.

  1991cited by this paper
• NB-598: a potent competitive inhibitor of squalene epoxidase.

  1990influential reference
• Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides.

  1990cited by this paper
• ras oncogenes: their role in neoplasia

  1990cited by this paper
• Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans.

  1989influential reference
• All ras proteins are polyisoprenylated but only some are palmitoylated.

  1989cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• ras genes.

  1987cited by this paper
• The p21 ras C-terminus is required for transformation and membrane association

  1984cited by this paper
• Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.

  1984cited by this paper
• Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro.

  1975cited by this paper

• In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.

  2021cites this paper
• Mechanisms of CaaX Protein Processing: Protein Prenylation by FTase and GGTase-I

  2020cites this paper
• Regulation of Ras signaling and function by plasma membrane microdomains.

  2017cites this paper
• Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.

  2017cites this paper
• The extracellular matrix protein EMILIN1 silences the RAS-ERK pathway via α4β1 integrin and decreases tumor cell growth

  2017cites this paper
• Transport to Rhebpress activity

  2016cites this paper
• How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.

  2016cites this paper
• Targets in anticancer research--A review.

  2015cites this paper
• Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.

  2013cites this paper
• treatment for hematologic malignancies? Targeting the Ras signaling pathway: a rational, mechanism-based

  2011cites this paper
• Working together: Farnesyl transferase inhibitors and statins block protein prenylation.

  2009cites this paper
• Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors.

  2007cites this paper
• Clinical activity of tipifarnib in hematologic malignancies

  2007cites this paper
• Development of farnesyl transferase inhibitors as anticancer agents: current status and future

  2007cites this paper
• Ras as a therapeutic target in hematologic malignancies

  2007cites this paper
• Thematic review series: Lipid Posttranslational Modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I Published, JLR Papers in Press, February 13, 2006.

  2006cites this paper
• Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms,and Progress in the Clinic

  2006cites this paper
• Cellular Mechanism of Arglabin-Dimethylaminohydrochloride Cytotoxicity

  2006cites this paper
• [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].

  2005cites this paper
• Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of Action

  2004cites this paper
• Role of farnesyltransferase inhibitors in hematologic malignancies

  2004cites this paper
• In vitro bone marrow granulocyte-macrophage progenitor cultures in the assessment of hematotoxic potential of the new drugs

  2004cites this paper
• Farnesyl Protein Transferase Inhibitors and Other Therapies Targeting the Ras Signal Transduction Pathway

  2004cites this paper
• Manumycin inhibits farnesyltransferase and induces apoptosis of drug‐resistant interleukin 6‐producing myeloma cells

  2002cites this paper
• Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.

  2002cites this paper
• Potent Suppression of Proliferation of A10 Vascular Smooth Muscle Cells by Combined Treatment with Lovastatin and 3-Allylfarnesol, an Inhibitor of Protein Farnesyltransferase

  2002influential citation
• Protein farnesyltransferase inhibitors.

  2002cites this paper
• Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms.

  2001cites this paper
• 4 Farnesyltransferase inhibitors

  2001cites this paper
• 2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.

  2001cites this paper
• Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.

  2000cites this paper
• Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited.

  2000cites this paper
• Farnesyltransferase and Geranylgeranyltransferase Inhibitors

  2000cites this paper
• Compositions et procedes d'inhibition de l'infection due au virus de l'immunodeficience humaine a l'aide de genes cellulaires humains a regulation negative

  2000cites this paper
• Farnesyl transferase inhibitors: current developments and future perspectives.

  2000cites this paper
• Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

  2000cites this paper
• Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue.

  2000cites this paper
• Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.

  1999cites this paper
• Inhibitors of protein prenylation 1999

  1999cites this paper
• Farnesyltransferase inhibitors: targeting the molecular basis of cancer.

  1999cites this paper
• Farnesyltransferase Inhibitors: Preclinical Development

  1999cites this paper
• Physico-chemical and biological analysis of true combinatorial libraries.

  1999cites this paper